Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 22


National trends in stroke after acute myocardial infarction among Medicare patients in the United States: 1999 to 2010.

Wang Y, Lichtman JH, Dharmarajan K, Masoudi FA, Ross JS, Dodson JA, Chen J, Spertus JA, Chaudhry SI, Nallamothu BK, Krumholz HM.

Am Heart J. 2015 Jan;169(1):78-85.e4. doi: 10.1016/j.ahj.2014.06.011. Epub 2014 Jun 14.


Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation.

Huber K, Connolly SJ, Kher A, Christory F, Dan GA, Hatala R, Kiss RG, Meier B, Merkely B, Pieske B, Potpara T, Stępińska J, Klun NV, Vinereanu D, Widimský P.

Int J Clin Pract. 2013 Jun;67(6):516-26. doi: 10.1111/ijcp.12147. Epub 2013 Apr 5. Review.


Plasminogen activators and ischemic stroke: conditions for acute delivery.

del Zoppo GJ.

Semin Thromb Hemost. 2013 Jun;39(4):406-25. doi: 10.1055/s-0033-1338126. Epub 2013 Mar 28. Review.


Outcomes associated with warfarin use in older patients with heart failure and atrial fibrillation and a cardiovascular implantable electronic device: findings from the ADHERE registry linked to Medicare claims.

Hess PL, Greiner MA, Fonarow GC, Klaskala W, Mills RM, Setoguchi S, Al-Khatib SM, Hernandez AF, Curtis LH.

Clin Cardiol. 2012 Nov;35(11):649-57. doi: 10.1002/clc.22064. Epub 2012 Oct 15.


VKORC1 pharmacogenetics and pharmacoproteomics in patients on warfarin anticoagulant therapy: transthyretin precursor as a potential biomarker.

Saminathan R, Bai J, Sadrolodabaee L, Karthik GM, Singh O, Subramaniyan K, Ching CB, Chen WN, Chowbay B.

PLoS One. 2010 Dec 13;5(12):e15064. doi: 10.1371/journal.pone.0015064.


Association of sequence variations in vitamin K epoxide reductase and gamma-glutamyl carboxylase genes with biochemical measures of vitamin K status.

Crosier MD, Peter I, Booth SL, Bennett G, Dawson-Hughes B, Ordovas JM.

J Nutr Sci Vitaminol (Tokyo). 2009 Apr;55(2):112-9.


Warfarin dose and INR related to genotypes of CYP2C9 and VKORC1 in patients with myocardial infarction.

Haug KBF, Sharikabad MN, Kringen MK, Narum S, Sjaatil ST, Johansen PW, Kierulf P, Seljeflot I, Arnesen H, Brørs O.

Thromb J. 2008 Jun 17;6:7. doi: 10.1186/1477-9560-6-7.


Drugs used in secondary prevention after myocardial infarction: case presentation.

Maxwell S, Waring WS.

Br J Clin Pharmacol. 2000 Nov;50(5):405-17. Review. No abstract available.


beta Blockade after myocardial infarction: systematic review and meta regression analysis.

Freemantle N, Cleland J, Young P, Mason J, Harrison J.

BMJ. 1999 Jun 26;318(7200):1730-7.


Modification of atherosclerosis by agents that do not lower cholesterol.

Cleland JG, Krikler DM.

Br Heart J. 1993 Jan;69(1 Suppl):S54-62. Review. No abstract available.


Antiplatelet therapy--Part I.

Goodnight SH, Coull BM, McAnulty JH, Taylor LM.

West J Med. 1993 Apr;158(4):385-92. Review.


Management of patients after their first myocardial infarction.

Flapan AD.

BMJ. 1994 Oct 29;309(6962):1129-34. Review.


Optimising heart failure pharmacotherapy: the ideal combination.

Cleland JG, Dutka DP.

Br Heart J. 1994 Aug;72(2 Suppl):S73-9. Review.


Cholesterol lowering does have a role in secondary prevention.

Wood DA.

Br Heart J. 1995 Jan;73(1):4-5. No abstract available.

Supplemental Content

Support Center